The U.S. Department of Homeland Security (DHS) added BGI Group, BGI Genomics Co. Ltd, and MGI Tech Co. Ltd to the Uyghur Forced Labor Prevention Act (UFLPA) Entity List on October 29, 2026, immediately triggering import prohibitions enforced by U.S. Customs and Border Protection (CBP). Clinical labs running DNBSEQ sequencing platforms, outsourcing genomic testing to BGI Genomics, or purchasing MGI Tech reagents must now execute supply-chain contingency plans.
Signed into law December 23, 2021, the UFLPA bars from U.S. import any goods produced wholly or in part in China's Xinjiang Uyghur Autonomous Region (XUAR) or by entities on the Entity List, unless the importer provides clear and convincing evidence of no forced labor involvement, as required under 19 U.S.C. § 1307. The BGI additions bring the UFLPA Entity List to 190 entities.
UFLPA Entity List: Which BGI Entities Are Designated
The designation covers three legal entities with interlocking roles across BGI's corporate structure. DHS found that BGI Group and BGI Genomics conduct genetic testing in Xinjiang and work with regional officials to recruit, transport, and receive forced labor from persecuted groups including Uyghurs; MGI Tech supplies the sequencing equipment and support services for that program. The designated entities are:
- BGI Group: parent holding company, also listed as Shenzhen BGI Technology Co. Ltd, headquartered in Shenzhen
- BGI Genomics Co. Ltd: publicly listed genomic testing subsidiary (Shenzhen Stock Exchange: 300676)
- MGI Tech Co. Ltd: sequencing instrument and reagent manufacturer
Both companies rejected the DHS findings: BGI Group stated it "has not engaged in any form of forced labor," while MGI Tech called the allegations "inconsistent with the facts." The UFLPA designation is separate from the Bureau of Industry and Security (BIS) Entity List, which restricts U.S. technology exports; BGI Research, BGI Tech Solutions (Hongkong) Co. Ltd, and Forensic Genomics International joined that list in March 2023 under distinct export-control authority. BGI Group and MGI Tech now face concurrent restrictions under the UFLPA import prohibition, the BIS Entity List, and Department of Defense Chinese Military Companies designations.
Lab Exposure: DNBSEQ Platforms, BGI Services, and the Divestiture Caveat
Labs running DNBSEQ platforms, using BGI Genomics sequencing services, or sourcing MGI Tech reagents face the most direct exposure under the ban. MGI Tech operated in the U.S. primarily through Complete Genomics, headquartered in San Jose, California, which commercially launched the DNBSEQ-G400 in August 2022 following the expiration of certain Illumina patents, then introduced the DNBSEQ-T7, DNBSEQ-E25, and DNBSEQ-G99 across portable low-volume to ultra-high-throughput tiers.
MGI Tech divested Complete Genomics in February 2026 to Switzerland-based Swiss Rockets AG for approximately $50 million, driven by anticipated Biosecure Act restrictions. As part of the transaction, Swiss Rockets acquired exclusive licensing rights to MGI's CoolMPS and StandardMPS sequencing chemistries in the United States and Canada. CBP applies the UFLPA's rebuttable presumption to goods, not companies; products sold under the Complete Genomics brand can be detained if CBP determines MGI Tech Co. Ltd produced them, and labs cannot treat the divestiture or brand labeling as evidence of supply-chain independence.
Outsourced BGI Sequencing Services Carry Separate Risk
BGI Genomics has historically operated CLIA-certified laboratories and provided outsourced sequencing services to U.S. clinical labs; congressional investigators previously raised concerns that Centers for Medicare and Medicaid Services (CMS) had accredited BGI-affiliated entities under CLIA. Labs submitting samples for outsourced whole-genome sequencing (WGS), whole-exome sequencing (WES), or RNA sequencing for oncology, rare disease, or infectious disease testing must now assess whether those service relationships involve import of goods from a UFLPA-listed entity. Legal guidance is recommended before initiating new sample submissions to BGI Genomics facilities.
Compliance Timeline: What Labs Must Do and When
The prohibition took effect October 29, 2026, with no grace period: any shipment arriving at a U.S. port of entry from a listed entity on or after that date is subject to CBP detention.
| Action Item | Applicable Entity | Deadline / Status |
|---|---|---|
| Audit active DNBSEQ reagent purchase orders | Labs using Complete Genomics or MGI Tech consumables | Immediate; effective Oct. 29, 2026 |
| Confirm manufacturing entity for each consumable SKU | All DNBSEQ platform operators | Immediate; request written statement from distributor |
| Review BGI Genomics outsourced sequencing contracts | Labs with active genomic testing agreements | Immediate; legal review recommended |
| Verify Complete Genomics supply-chain independence | Labs running DNBSEQ instruments post-Feb. 2026 | Confirm with vendor; CBP applies to goods, not brand |
| Qualify alternative NGS platforms for capital planning | All affected labs | FY2027 budget cycle; begin vendor qualification now |
| Consult legal counsel on UFLPA rebuttable presumption | Any lab with open shipments potentially tied to MGI Tech | Immediate if shipments are in transit |
Labs that received all reagents under existing standing orders before October 29, 2026, may face no immediate supply disruption. Any subsequent replenishment sourced from MGI Tech Co. Ltd is subject to CBP review from that date forward.
Evaluating NGS Alternatives: CLIA Requirements and Platform Fit
Platform transitions must account for CLIA method verification and validation requirements, not only capital cost and throughput fit. The NGS instrument market includes platforms from multiple U.S.- and European-based vendors, spanning benchtop instruments for moderate-complexity clinical research to ultra-high-throughput systems for population genomics and oncology panel testing. Labs should evaluate alternatives by test menu, CLIA complexity category, validated library preparation workflows, and existing bioinformatics infrastructure.
Under CLIA regulations at 42 CFR Part 493, Subpart K (Quality System for Nonwaived Testing, §493.1253), labs must establish and verify performance specifications for any new test system or method change before reporting patient results. Modification of an FDA-cleared method triggers full method validation rather than performance verification alone. Labs moving off DNBSEQ platforms should also revisit per-sample cost models, as no current replacement platform matches that cost profile across all throughput categories, and both regulatory validation and procurement lead times should factor into transition planning.
Does the BIOSECURE Act Change the Calculus for Federally Funded Labs?
Federally funded clinical labs face compliance obligations that extend beyond the UFLPA's immediate border enforcement. Enacted December 18, 2025, as Section 851 of the National Defense Authorization Act (NDAA) for Fiscal Year 2026, the BIOSECURE Act prohibits federal agencies from contracting with entities that use biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), defined by the Department of Defense's Section 1260H list, which includes BGI Group, BGI Genomics, and MGI Tech. Those prohibitions are not yet active: OMB must publish a BCC list by December 2026, and enforcement begins 60 days after the Federal Acquisition Regulation is updated; labs under federal grants, Medicare/Medicaid billing, or government research contracts should monitor OMB guidance and consult compliance counsel.
The UFLPA is the more immediate instrument for all labs, regardless of funding source. A private clinical laboratory with no government contracts faces identical CBP enforcement if it imports goods produced by a UFLPA-listed entity; that presumption is statutory, rebuttable only with CBP-approved evidence, and historically difficult to overcome for goods with verified Xinjiang production links.
UFLPA, BIOSECURE Act, BGI, MGI Tech: Key Takeaways for Clinical Labs
The October 29, 2026, UFLPA designation of BGI Group, BGI Genomics, and MGI Tech creates an immediate import prohibition that applies to all clinical labs, regardless of federal funding status, existing contracts, or the Complete Genomics divestiture. Labs with active BGI Genomics or MGI Tech relationships, whether through outsourced sequencing services or installed DNBSEQ platforms, face distinct but concurrent compliance obligations, each requiring legal review and, where platform transition is necessary, CLIA method verification or validation under 42 CFR Part 493, Subpart K (§493.1253) before reporting patient results. Regulatory pressure on Chinese genomics companies is intensifying across concurrent U.S. authorities, including UFLPA, BIS, DoD, and the BIOSECURE Act; labs should treat this designation as the start of an ongoing compliance obligation, not an isolated procurement event.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.





